RxDoctor Payments Data

Christopher Neagra, DO

Nephrology · Glendale, AZNPI 1780034306

Payments from drug & device makers

$3,358in general payments, 2019–2025

Across 153 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$490
  • AstraZeneca$420
  • Daiichi Sankyo Inc.$396
  • Bayer$270
  • Boehringer Ingelheim$242
  • Calliditas Therapeutics US Inc.$194
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,356100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,358 in reported general payments places this provider in the 55th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$147,917
Medicare patients
293
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol50$51,454
JardianceEmpagliflozin19$29,258
LokelmaSodium Zirconium Cyclosilicate31$25,398
Cinacalcet Hcl11$16,072
Nifedipine ErNifedipine105$3,455
Tamsulosin Hcl73$829
Losartan Potassium67$705
Lisinopril105$611
Furosemide74$513
Carvedilol65$469
Hydralazine Hcl31$437
Finasteride41$375
Bumetanide13$368
Olmesartan Medoxomil24$236
Allopurinol16$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$420$76,85281 claims
Boehringer IngelheimJardiance$242$29,25819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 259 nephrology providers in Arizona.

Other nephrology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →